TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 18, 2002

Primary Completion Date

May 19, 2006

Study Completion Date

May 19, 2006

Conditions
Myeloma
Interventions
DRUG

Topotecan

After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.

DRUG

Cyclophosphamide

After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.

DRUG

Melphalan

After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.

OTHER

Peripheral Blood Stem Cells

On Day 7, some or all of the stem cells will be reinfused.

Trial Locations (1)

77030

U.T. M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

SmithKline Beecham

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER